Genetics Play Key Role in Determining Success of Weight-Loss Drugs, Study Reveals

Behind the staggering success stories of celebrities like Meghan Trainor and Rosie O'Donnell, who have lost 60lbs and over 50lbs respectively while on weight-loss drugs, lies a hidden truth: not everyone benefits equally from medications like Ozempic, Wegovy, or Mounjaro. A groundbreaking study involving 28,000 individuals on GLP-1 receptor agonists has revealed that genetic predispositions may dictate who thrives on these drugs—and who risks severe side effects. Researchers in California analyzed DNA samples and found two genetic variants that could explain the wide disparity in weight loss outcomes and gastrointestinal distress among users.

The study, which tracked participants over eight months, found that people taking GLP-1 medications lost an average of 25lbs (11.3kg). Yet, some individuals shed far more weight than others. The key to this discrepancy, scientists say, may lie in the DNA. One variant, rs10305420, located on a gene tied to hunger hormones, was found to enhance weight loss. Those with one copy of the variant lost an additional 1.7lbs (0.7kg) on average, while those with two copies lost 3lbs (1.4kg) more. This genetic marker appears common in Europeans, with 64% carrying at least one copy, but is rare in other populations, such as African Americans, where only 7% have it.

"This variant may boost weight loss by increasing the number of GLP-1 receptors in the body, making the drugs more effective," said Dr. Adam Auton, a study co-author and genetics researcher. The findings, published in a peer-reviewed journal, suggest that the body's innate response to these medications is not just about adherence or diet—it's written into the code of our DNA.

Yet, the same genetic blueprint that enhances weight loss may also amplify side effects. Another variant, rs1800437, linked to the GIPR gene, was found to correlate with a higher likelihood of nausea, constipation, and vomiting. Among users of tirzepatide, the active ingredient in Mounjaro and Zepbound, those with two copies of this variant were 15 times more likely to experience vomiting. For individuals with two copies of both variants, the risk of severe side effects skyrockets, potentially leading to drug discontinuation.

"Suffering from side effects can make the drugs less effective because it increases the chance of missing doses or quitting altogether," warned Dr. Ruth Loos, a genetic epidemiologist at the University of Copenhagen, who was not involved in the study. She noted that the extra weight loss seen in those with the rs10305420 variant—though seemingly small—equates to about 10% of total bodyweight, a significant difference for someone battling obesity.

The implications of these findings are profound. For individuals like Whoopi Goldberg, who has lost the weight of "two people" on Mounjaro, the absence of known genetic markers may mean their success is purely circumstantial. Yet, for others, their DNA could be the deciding factor in whether these drugs work—or whether they become a health hazard. The study also highlights a critical gap: while the variants are common in Europeans, their prevalence in other populations remains unclear.

"These results make perfect biological sense," said Dr. Auton. "The genetic variant we found lands right in the GLP-1 receptor gene, which is the target for these medications." But the research also raises ethical questions. If genetic testing becomes routine, will patients be able to access personalized treatment plans? Or will this information create new disparities in healthcare access?

For now, the study offers a glimpse into the future of precision medicine. Yet, it also underscores a sobering reality: while weight-loss drugs may revolutionize obesity treatment, their power—and their risks—are not evenly distributed. For some, these medications are a miracle. For others, they may be a minefield. And for all, the journey to weight loss is far more complex than a simple pill can solve.

Semaglutide and tirzepatide represent two distinct approaches in the fight against obesity, each targeting different hormonal pathways. Semaglutide acts primarily on the GLP-1 (glucagon-like peptide-1) pathway, which regulates insulin release, stomach emptying, and appetite. However, tirzepatide extends its reach by also engaging the GIP (glucose-dependent insulinotropic polypeptide) pathway. This dual-action mechanism has sparked interest among scientists, who suggest it may reduce the likelihood of gastrointestinal side effects such as nausea—a common issue with GLP-1 agonists. The distinction between these two drugs highlights a growing trend in pharmaceutical research: tailoring treatments to maximize efficacy while minimizing adverse effects.

The findings, published in *Nature*, emerged from a large-scale study conducted by researchers at 23andMe, a leading DNA testing platform. By analyzing data from its database, the team sought to uncover genetic factors that influence how individuals respond to weight-loss medications. The study involved over 28,000 participants, with a significant portion of them taking either Ozempic or Wegovy (semaglutide-based drugs) or Mounjaro and Zepbound (tirzepatide-based drugs). A smaller group used compounded versions of semaglutide or tirzepatide. The participants, predominantly obese adults averaging 52 years old, showed a notable demographic skew: 84% were female, and nearly 80% identified as white. These statistics underscore the limitations of the study's diversity but also emphasize the potential for genetic testing to personalize treatment strategies in the future.

The researchers emphasized that their work could pave the way for more customized weight-loss medications. By identifying genetic variants associated with drug responses, individuals might one day choose therapies that align with their biology. For example, someone with a genetic profile that predisposes them to nausea might benefit more from tirzepatide's dual pathway approach, while others could thrive on semaglutide. However, the study also revealed that side effects remain a significant hurdle. Approximately 20% of participants reported experiencing constipation or a diminished sense of pleasure from eating, while 10% cited stomach pain. These findings suggest that while newer drugs like tirzepatide may offer advantages, they are not without their own challenges.

The implications of this research extend beyond individual patient outcomes. They signal a shift in how obesity is treated—moving from a one-size-fits-all model to a more nuanced, data-driven approach. As genetic testing becomes more accessible, patients could gain insights into how their bodies interact with medications, enabling more informed decisions. Yet, the study's demographic limitations raise questions about whether these findings will apply broadly. For now, the data serve as a foundation for future research, one that promises to refine the science of weight management and improve the lives of millions struggling with obesity.